Tirzepatide and pancreatitis: one case

A case report published on 1 August 2026 in Cardiovascular Diabetology Endocrinology Reports describes a woman given tirzepatide after repeated attacks of hypertriglyceridemia-mediated acute pancreatitis. Over 12 months of follow-up her triglycerides normalised, her insulin was withdrawn, and she had no further pancreatitis episodes^[1]. That reads like a clean result. It is also one patient, which is the weakest tier of clinical evidence there is.

The report comes from a group at LMU University Hospital in Munich (Lechner, Lechner, Freibothe and Vogt), and it matters because it runs against the grain. Acute pancreatitis is a labelled warning for tirzepatide, and the authors open by noting that incretin-based therapy is often withheld from patients with a history of pancreatitis precisely because current recommendations discourage it^[1].

What the case describes

The patient was born in 1993. She had severe hypertriglyceridemia known since 2018, type 2 diabetes diagnosed in 2022, recurrent hypertriglyceridemia-mediated acute pancreatitis from 2023 onward, chronic fibrosing pancreatitis, and severe metabolic dysfunction-associated steatotic liver disease (MASLD, the current term for fatty liver driven by metabolic disease)^[1].

Lifestyle measures, fenofibrate, high-dose omega-3 fatty acids and intensified insulin therapy had all been tried. In March 2025 she presented again with acute pancreatitis and triglycerides of 4,400 mg/dL^[1]. For scale, the registered trial protocol in this area defines a qualifying hypertriglyceridemic episode as triglycerides above 1,000 mg/dL, or 500 to 1,000 mg/dL with chylous serum and no other identifiable cause^[6].

Tirzepatide was started on 27 March 2025. At three months her triglycerides were 137 mg/dL and at twelve months 85 mg/dL. HbA1c fell from 7.0% to 5.5%, insulin was fully discontinued, inflammatory markers normalised, and no further pancreatitis occurred during the follow-up^[1].

The detail that changes how you read it

Tirzepatide did not do the initial heavy lifting on the triglycerides, and the paper says so plainly. The acute pancreatitis was stabilised first, and the triglycerides came down through prolonged fasting and intensified insulin therapy before tirzepatide was introduced. By the day tirzepatide was started, triglycerides were already 335 mg/dL, not 4,400^[1].

So the collapse from 4,400 to 335 mg/dL belongs to fasting and insulin. What tirzepatide is credited with is the stretch that followed: triglycerides held at normal levels for a year, insulin withdrawn, and no recurrence over that window. The authors are careful with the claim. Their stated conclusion is that the favourable course "represents an association only and does not establish causality"^[1].

Pancreatitis is a warning on this drug's label

The US prescribing information for Mounjaro lists acute pancreatitis under Warnings and Precautions. The label states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or with Mounjaro, tells prescribers to watch for persistent or severe abdominal pain after starting the drug, and instructs them to discontinue Mounjaro if pancreatitis is suspected^[2]. Tirzepatide is prescription-only across every market we cover, centrally authorised in the EU since September 2022 with Eli Lilly Nederland as marketing authorisation holder^[3]. In Germany, where this patient was treated, that authorisation governs how tirzepatide is supplied.

The case literature points both ways. In JCEM Case Reports in 2025, Grennan and colleagues described a 64-year-old woman without diabetes who developed fulminant necrotizing pancreatitis days after her second 2.5 mg dose of tirzepatide and died on hospital day three, and argued that necrotizing pancreatitis deserves a boxed warning^[4]. Pulling in the other direction, a 2025 review in the Cleveland Clinic Journal of Medicine by Mehta, Lomeli and Pantalone argues the class-wide pancreatitis signal tracks rapid weight loss more than the drugs themselves, cites LEADER where pancreatitis rates were 0.4% on liraglutide versus 0.5% on placebo, and concludes clinicians should not rule out GLP-1 receptor agonists on prior pancreatitis alone^[5]. That is a review-level argument, not a guideline change.

What one case can and cannot tell you

A case report sits at the bottom of the evidence hierarchy. No control group, no randomisation, no blinding, and no way to separate the drug from everything else that shifted at the same time. This patient stopped insulin, was under specialist follow-up at a university hospital for a year, and had already been through a fasting and insulin protocol that dropped her triglycerides more than tenfold. Any of that could account for part of the outcome. Publication also runs one way: cases that end well get written up more often than cases that do not, so the published case record is not a fair sample of what happens in practice.

That is not a reason to ignore it. Case reports are how a hypothesis gets onto the record, and this one is a reasonable hypothesis. It is a reason to read it as a question rather than an answer, and specifically not as evidence that tirzepatide is safe to use after pancreatitis.

What would actually settle it

A randomised trial, and one is registered. RECAP-GLP1 (NCT07617155), sponsored by Peking Union Medical College Hospital, is a phase 4 randomised, quadruple-masked trial planning to enrol 396 adults with a history of hypertriglyceridemia-induced acute pancreatitis. The primary outcome is the proportion of participants with a recurrent episode within 18 months of randomisation. It was first posted in June 2026, is not yet recruiting, and lists an estimated start of September 2026 and primary completion in September 2028^[6].

Two caveats worth holding. The trial tests semaglutide, starting at 0.25 mg weekly and escalating to 0.5 mg, rather than tirzepatide^[6], so it will answer a question about the class before it answers one about this molecule. And nothing reads out before late 2028.

Until then the honest position is the one on our tirzepatide page: pancreatitis stays on the label as a listed risk, the published cases disagree with each other, and one patient in Munich does not move the risk and benefit calculation for anyone else. This article is educational and is not medical advice. Any decision about incretin therapy after pancreatitis belongs with a clinician who knows the full history.